Table 2.
Univariate analysis between those who received neoadjuvant therapy and those who did not
| Variable | Total N = 23 |
Neoadjuvant | p Value | |
|---|---|---|---|---|
| Yes N = 12 |
No N = 11 |
|||
| Gender | ||||
| Female | 5 | 3 (60%) | 2 (40%) | 0.99 |
| Male | 18 | 9 (50%) | 9 (50%) | |
| Negative resection margin | ||||
| No | 5 | 4 (80%) | 1 (20%) | 0.317 |
| Yes | 18 | 8 (44%) | 10 (56%) | |
| Smoking | ||||
| Missing | 1 | 0 | 1 | 0.99 |
| Ex-smoker | 4 | 2 (50%) | 2 (50%) | |
| No | 12 | 7 (58%) | 5 (42%) | |
| Yes | 6 | 3 (50%) | 3 (50%) | |
| Stage | ||||
| I | 3 | 1 (33%) | 2 (67%) | 0.013 |
| II | 5 | 0 | 5 (100%) | |
| III | 3 | 2 (67%) | 1 (33%) | |
| IV | 12 | 9 (75%) | 3 (25%) | |
| Histology | ||||
| A | 1 | 0 | 1 (9.1%) | 0.99 |
| AB | 4 | 2(16.7%) | 2 (18.2%) | |
| BI | 1 | 0 | 1 (100%) | |
| BII | 8 | 4 (50%) | 4 (50%) | |
| BIII | 9 | 6 (67%) | 3 (33%) | |
| Surgical approach | ||||
| Open | 12 | 10 (83%) | 2 (17%) | 0.002 |
| VATS | 11 | 2 (18%) | 9 (82%) | |
| Adjuvant therapy | ||||
| No | 8 | 5 (63%) | 3 (38%) | 0.667 |
| Yes | 15 | 7 (47%) | 8 (53%) | |
| Complications | ||||
| No | 17 | 8 (47%) | 9 (53%) | 0.640 |
| Yes | 6 | 4 (67%) | 2 (33%) | |
| Lymphovascular invasion | ||||
| Missing | 7 | 4 (57%) | 3 (43%) | 0.282 |
| No | 11 | 4 (36%) | 7 (64%) | |
| Yes | 5 | 4 (80%) | 1 (20%) | |
| Myasthenia gravis diagnosis | ||||
| No | 18 | 11 (61%) | 7 (39%) | 0.155 |
| Yes | 5 | 1 (20%) | 4 (80%) | |
| Current status | ||||
| Alive | 22 | 11 (50%) | 11 (50%) | 0.99 |
| Dead | 1 | 1 (100%) | 0 | |
| Recurrence | ||||
| No | 18 | 8 (44%) | 10 (56%) | 0.317 |
| Yes | 5 | 4 (80%) | 1 (20%) | |
| Cystic component | ||||
| Missing | 3 | 2 (67%) | 1 (33%) | 0.474 |
| No | 18 | 10 (56%) | 8 (44%) | |
| Yes | 2 | 0 | 2 (100%) | |